Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. Researchers at Case Western Reserve School of Medicine have found that semaglutide,

A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing Alzheimer’s disease.

Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

Ozempic has quickly become a household name with medical researchers claiming the breakthrough drug can have many benefits.